Inotiv, Inc.
About Inotiv, Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $513.0M
- Net income
- -$68.6M
- Total assets
- $771.1M
- Market cap
- $5.8M
- Operating margin
- -6.0%
- Net margin
- -13.4%
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $513.0M
- Operating expenses
- $543.9M
- Operating income
- -$30.9M
- Income tax
- -$19.1M
- Net income
- -$68.6M
- EPS (basic)
- $-2.11
- EPS (diluted)
- $-2.11
Balance sheet
- Total assets
- $771.1M
- Current assets
- $194.6M
- Total liabilities
- $635.1M
- Current liabilities
- $556.8M
- Shareholders’ equity
- $136.0M
Cash flow
- Operating cash flow
- -$10.5M
- Investing cash flow
- -$12.9M
- Financing cash flow
- $23.7M
- Net cash flow
- $309.0K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $5.8M
- EPS (diluted)
- $-2.11
- Shares outstanding
- 72.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 25, 1997
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $68.6M in FY2025.
- Revenue grew 473% from FY2021 to FY2025.
- Trading 97% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Inotiv, Inc..
Write a review
News about Inotiv, Inc.
News & sentiment via Polygon.io
